We are glad to announce that the DEEP-2 study Phase III multicentre, randomised, open label, non-inferiority active-controlled trial aimed at comparing for the first time the efficacy of deferiprone (DFP) versus deferasirox (DFX) in paediatric patients aged from 1 month to less than 18 years […]
The DEEP project has received research funding from the European Union under the 7th Framework Programme
News
DEEP project – “Success story” for European Commission’s DG Research and Innovation
The European Commission’s DG Research and Innovation published on the European Commission (EC) official website an article regarding the successful outcomes of the DEEP project (DEferiprone Evaluation in Paediatrics), as an example of particularly fruitful project. DEEP is a 6-year European project coordinated by Consorzio per […]
DEEP Final meeting: preliminary results
The DEEP (DEferiprone Evaluations in paediatrics) project, a 6-year European Project (FP7) coordinated by CVBF and comprising 23 recruiting centres in European and non-European countries, scientific partners from several European countries and a pharmaceutical group based in Canada, is at the final rush and has presented […]
Drug safety of oral iron chelator deferiprone in children: a dissertation on the results of DEEP-3 Study
On September 21st 2017, Sebastian Botzenhardt, researcher involved in DEEP project (DEEP PhD), held the final examination for his doctoral thesis at Friedrich-Alexander-University Erlangen-Nuremberg, where he exposed the overall results of a study aimed to assess the drug safety profile of oral chelator deferiprone (DFP […]